Loading clinical trials...
Loading clinical trials...
To Evaluate the Single-arm, Multi-center Phase II Clinical Trial of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
Conditions
Interventions
Benmelstobart injection combined with Anlotinib hydrochloride capsule
Locations
15
China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Army Medical University of the People's Liberation Army of China
Chongqing, Chongqing Municipality, China
Sun Yat-sen University Cancer Center
Guangdong, Guangdong, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Start Date
April 2, 2026
Primary Completion Date
November 1, 2027
Completion Date
November 1, 2028
Last Updated
April 23, 2026
NCT06066138
NCT04332874
NCT06813417
NCT06789081
NCT06827886
NCT01614795
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions